Sfoglia per Rivista
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
2011-01-01 Barosi G; Bosi A; Abbracchio MP; Danesi R; GENAZZANI, Armando; Corradini P; Pane F; Tura S.
[Kinetic and immunological studies in human myeloma: clinical implications (author's transl)]
1979-01-01 PILERI A ;BOCCADORO M
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
2019-01-01 Ferrero, Simone; Rossi, Davide; Rinaldi, Andrea; Bruscaggin, Alessio; Spina, Valeria; Eskelund, Christian W; Evangelista, Andrea; Moia, Riccardo; Kwee, Ivo; Dahl, Christina; Di Rocco, Alice; Stefoni, Vittorio; Diop, Fary; Favini, Chiara; Ghione, Paola; Mahmoud, Abdurraouf Mokhtar; Schipani, Mattia; Kolstad, Arne; Barbero, Daniela; Novero, Domenico; Paulli, Marco; Zamò, Alberto; Jerkeman, Mats; Gomez da Silva, Maria; Santoro, Armando; Molinari, Annalia; Ferreri, Andres; Grønbæk, Kirsten; Piccin, Andrea; Cortelazzo, Sergio; Bertoni, Francesco; Ladetto, Marco; Gaidano, Gianluca
Late deaths among five-year survivors of childhood cancer. A population-based study in Piedmont Region, Italy.
2006-01-01 DAMA E ;PASTORE G ;MOSSO ML ;FERRANTE D ;MAULE MM ;MAGNANI C ;MERLETTI F
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
2017-01-01 Autore, F; Strati, P; Innocenti, I; Corrente, F; Trentin, L; Cortelezzi, A; Visco, C; Coscia, M; Cuneo, A; Gozzetti, A; Mauro, FR; Montillo, M; Gentile, M; Morabito, F; Molica, S; Falcucci, P; D'Arena, G; Murru, R; Vincelli, D; Galieni, P; Reda, G; Tisi, MC; Vitale, C; Rigolin, GM; Ferrajoli, A; Laurenti, L
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
2017-01-01 Autore, F; Strati, P; Innocenti, I; Corrente, F; Trentin, L; Cortelezzi, A; Visco, C; Coscia, M; Cuneo, A; Gozzetti, A; Mauro, FR; Montillo, M; Gentile, M; Morabito, F; Molica, S; Falcucci, P; D'Arena, G; Murru, R; Vincelli, D; Galieni, P; Reda, G; Tisi, MC; Vitale, C; Rigolin, GM; Ferrajoli, A; Laurenti, L
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
2019-01-01 Vitale, Candida; Ferrajoli, Alessandra*
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
2015-01-01 Fiorcari S1; Martinelli S1; Bulgarelli J1; Audrito V2; Zucchini P1; Colaci E1; Potenza L1; Narni F1; Luppi M1; Deaglio S2; Marasca R3; Maffei R1.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
2019-01-01 Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra
Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
2006-01-01 De Franceschi L;Daraio F;Filippini A;Carturan S;Muchitsch EM;Roetto A;Camaschella C
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
2009-01-01 Bruno B; Sorasio R; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Festuccia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Ciccone G; Boccadoro M
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
2019-01-01 Maffini E.; Storer B.E.; Sandmaier B.M.; Bruno B.; Sahebi F.; Shizuru J.A.; Chauncey T.R.; Hari P.; Lange T.; Pulsipher M.A.; McSweeney P.A.; Holmberg L.; Becker P.S.; Green D.J.; Mielcarek M.; Maloney D.G.; Storb R.
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
2017-01-01 Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I; Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients
2020-01-01 Baron F.; Efficace F.; Cannella L.; Willemze R.; Vignetti M.; Muus P.; Marie J.-P.; Ferrero D.; Fazi P.; Sala E.L.; Bourhis J.-H.; Fabbiano F.; Bosi A.; Sborgia M.; Martinelli G.; Wittnebel S.; Trisolini S.; Petti M.C.; Halkes C.J.M.; van der Velden W.J.F.M.; de Witte T.; Amadori S.; Zittoun R.A.; Suciu S.
Long-term molecular responses to imatinib inpatients with chronic myeloid leukemia: comparison between complete cytogeneticresponders treated in early and in late chronic phase.
2007-01-01 Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
2015-01-01 Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; D'Adda, M; Stagno, F; Tiribelli, M; Salvucci, M; Fava, C; Martino, B; Cedrone, M; Bocchia, M; Trabacchi, E; Cavazzini, F; Usala, E; Russo Rossi, A; Bochicchio, Mt; Soverini, S; Alimena, G; Cavo, M; Pane, F; Martinelli, G; Saglio, G; Baccarani, M; Rosti, G
Loss of surface HLA class I molecules in leukemic myeloblasts is correlated with an increased leukocyte concentration at onset.
1992-01-01 SAVOIA P ;D'ALFONSO S ;PERUCCIO D ;ISABELLA N ;FALDA M ;RESEGOTTI L ;RICHIARDI P
Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
2007-01-01 BERNENGO MG; QUAGLINO P; COMESSATTI A; ORTONCELLI M; NOVELLI M; LISA F; FIERRO MT
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
2001-01-01 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M
M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia.
1992-01-01 ZACCARIA A ;MARTINELLI G ;BUZZI M ;ZUFFA E ;ZAMAGNI MD ;TESTONI N ;RUSSO D ;GUERRASIO A ;SAGLIO G ;TURA S
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation | 2011 | Barosi G; Bosi A; Abbracchio MP; Danesi R; GENAZZANI, Armando; Corradini P; Pane F; Tura S. | |
| [Kinetic and immunological studies in human myeloma: clinical implications (author's transl)] | 1979 | PILERI A ;BOCCADORO M | |
| KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study | 2019 | Ferrero, Simone; Rossi, Davide; Rinaldi, Andrea; Bruscaggin, Alessio; Spina, Valeria; Eskelund, Christian W; Evangelista, Andrea; Moia, Riccardo; Kwee, Ivo; Dahl, Christina; Di Rocco, Alice; Stefoni, Vittorio; Diop, Fary; Favini, Chiara; Ghione, Paola; Mahmoud, Abdurraouf Mokhtar; Schipani, Mattia; Kolstad, Arne; Barbero, Daniela; Novero, Domenico; Paulli, Marco; Zamò, Alberto; Jerkeman, Mats; Gomez da Silva, Maria; Santoro, Armando; Molinari, Annalia; Ferreri, Andres; Grønbæk, Kirsten; Piccin, Andrea; Cortelazzo, Sergio; Bertoni, Francesco; Ladetto, Marco; Gaidano, Gianluca | |
| Late deaths among five-year survivors of childhood cancer. A population-based study in Piedmont Region, Italy. | 2006 | DAMA E ;PASTORE G ;MOSSO ML ;FERRANTE D ;MAULE MM ;MAGNANI C ;MERLETTI F | |
| LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA | 2017 | Autore, F; Strati, P; Innocenti, I; Corrente, F; Trentin, L; Cortelezzi, A; Visco, C; Coscia, M; Cuneo, A; Gozzetti, A; Mauro, FR; Montillo, M; Gentile, M; Morabito, F; Molica, S; Falcucci, P; D'Arena, G; Murru, R; Vincelli, D; Galieni, P; Reda, G; Tisi, MC; Vitale, C; Rigolin, GM; Ferrajoli, A; Laurenti, L | |
| LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA | 2017 | Autore, F; Strati, P; Innocenti, I; Corrente, F; Trentin, L; Cortelezzi, A; Visco, C; Coscia, M; Cuneo, A; Gozzetti, A; Mauro, FR; Montillo, M; Gentile, M; Morabito, F; Molica, S; Falcucci, P; D'Arena, G; Murru, R; Vincelli, D; Galieni, P; Reda, G; Tisi, MC; Vitale, C; Rigolin, GM; Ferrajoli, A; Laurenti, L | |
| Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia | 2019 | Vitale, Candida; Ferrajoli, Alessandra* | |
| Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. | 2015 | Fiorcari S1; Martinelli S1; Bulgarelli J1; Audrito V2; Zucchini P1; Colaci E1; Potenza L1; Narni F1; Luppi M1; Deaglio S2; Marasca R3; Maffei R1. | |
| Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial | 2019 | Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra | |
| Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. | 2006 | De Franceschi L;Daraio F;Filippini A;Carturan S;Muchitsch EM;Roetto A;Camaschella C | |
| LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA | 2009 | Bruno B; Sorasio R; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Festuccia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Ciccone G; Boccadoro M | |
| Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma | 2019 | Maffini E.; Storer B.E.; Sandmaier B.M.; Bruno B.; Sahebi F.; Shizuru J.A.; Chauncey T.R.; Hari P.; Lange T.; Pulsipher M.A.; McSweeney P.A.; Holmberg L.; Becker P.S.; Green D.J.; Mielcarek M.; Maloney D.G.; Storb R. | |
| LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE | 2017 | Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I; Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I | |
| Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients | 2020 | Baron F.; Efficace F.; Cannella L.; Willemze R.; Vignetti M.; Muus P.; Marie J.-P.; Ferrero D.; Fazi P.; Sala E.L.; Bourhis J.-H.; Fabbiano F.; Bosi A.; Sborgia M.; Martinelli G.; Wittnebel S.; Trisolini S.; Petti M.C.; Halkes C.J.M.; van der Velden W.J.F.M.; de Witte T.; Amadori S.; Zittoun R.A.; Suciu S. | |
| Long-term molecular responses to imatinib inpatients with chronic myeloid leukemia: comparison between complete cytogeneticresponders treated in early and in late chronic phase. | 2007 | Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML. | |
| Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia | 2015 | Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; D'Adda, M; Stagno, F; Tiribelli, M; Salvucci, M; Fava, C; Martino, B; Cedrone, M; Bocchia, M; Trabacchi, E; Cavazzini, F; Usala, E; Russo Rossi, A; Bochicchio, Mt; Soverini, S; Alimena, G; Cavo, M; Pane, F; Martinelli, G; Saglio, G; Baccarani, M; Rosti, G | |
| Loss of surface HLA class I molecules in leukemic myeloblasts is correlated with an increased leukocyte concentration at onset. | 1992 | SAVOIA P ;D'ALFONSO S ;PERUCCIO D ;ISABELLA N ;FALDA M ;RESEGOTTI L ;RICHIARDI P | |
| Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. | 2007 | BERNENGO MG; QUAGLINO P; COMESSATTI A; ORTONCELLI M; NOVELLI M; LISA F; FIERRO MT | |
| Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. | 2001 | Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M | |
| M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. | 1992 | ZACCARIA A ;MARTINELLI G ;BUZZI M ;ZUFFA E ;ZAMAGNI MD ;TESTONI N ;RUSSO D ;GUERRASIO A ;SAGLIO G ;TURA S |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile